(Q32038981)

5 July 2017

title

Pharmacokinetic and pharmacodynamic modeling of NN703, a growth hormone secretagogue, after a single po dose to human volunteers (English)

1 reference

5 July 2017

1 reference

1 reference

Agersø H

1

1 reference

5 July 2017

Ynddal L

series ordinal

2

1 reference

5 July 2017

Søgaard B

series ordinal

3

1 reference

5 July 2017

Zdravkovic M

series ordinal

4

1 reference

5 July 2017

language of work or name

1 reference

1 February 2001

1 reference

The Journal of Clinical Pharmacology

5 July 2017

published in

1 reference

5 July 2017

volume

41

1 reference

5 July 2017

issue

2

1 reference

5 July 2017

page(s)

163-169

1 reference

Growth hormone therapy of short stature

5 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009971

Ipamorelin, the first selective growth hormone secretagogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009971

A new series of highly potent growth hormone-releasing peptides derived from ipamorelin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009971

Novel orally active growth hormone secretagogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009971

Peptidomimetic regulation of growth hormone secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009971

Growth hormone secretagogues. Clinical experience and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009971

Growth hormone-releasing peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009971

Pharmacological characterisation of a new oral GH secretagogue, NN703

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009971

The pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of NN703, a novel orally active growth hormone secretagogue in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009971

Pharmacokinetic-pharmacodynamic relationships in phase I/phase II of drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009971

Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009971

Methodological issues in pharmacokinetic-pharmacodynamic modelling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009971

Comparison of four basic models of indirect pharmacodynamic responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009971

Characterization of four basic models of indirect pharmacodynamic responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009971

Characteristics of indirect pharmacodynamic models and applications to clinical drug responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009971

Biochemical, cellular, and pharmacological aspects of the multidrug transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009971

Growth hormone responses to continuous infusions of growth hormone-releasing hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009971

Twenty-four-hour growth hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specifically attenuates the response to a subsequent GHRP bolus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009971

Desensitization studies using perifused rat pituitary cells show that growth hormone-releasing hormone and His-d-Trp-Ala-Trp-d-Phe-Lys-NH2 stimulate growth hormone release through distinct receptor sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009971

The interaction of growth hormone releasing hormone and somatostatin in the generation of a GH pulse in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009971

Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009971

Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009971

Growth hormone-releasing effect of oral growth hormone-releasing peptide 6 (GHRP-6) administration in children with short stature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009971

Physiologic indirect response models characterize diverse types of pharmacodynamic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009971

Integrated functions for four basic models of indirect pharmacodynamic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009971

Repeat administration of the GH secretagogue MK-0677 increases and maintains elevated IGF-I levels in beagles

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009971

Impaired inhibitory effects of somatostatin on growth hormone (GH)-releasing hormone stimulation of GH secretion after short term infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122009971

10.1177/00912700122009971

21 January 2018

Identifiers

DOI

1 reference

5 July 2017

1 reference